Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Circulating tumor DNA using a plasma-only assay predicts survival in patients with oligometastatic colorectal cancer after definitive therapy.

A single-center prospective study used Guardant Reveal to test whether ctDNA after definitive therapy for oligometastatic colorectal cancer was associated with outcome.

Journal of Gastrointestinal OncologyPubMed 40386606DOI 10.21037/jgo-24-819